Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

BACKGROUND: Psilocybin may help treat obsessive–compulsive disorder (OCD). To date, only one open-label study of psilocybin for OCD exists, necessitating further investigation with a randomized controlled design. The neural correlates of psilocybin’s effects on OCD have also not been studied. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ching, Terence H. W., Grazioplene, Rachael, Bohner, Calvin, Kichuk, Stephen A., DePalmer, Giuliana, D’Amico, Elizabeth, Eilbott, Jeffrey, Jankovsky, Anastasia, Burke, Michelle, Hokanson, Jamila, Martins, Brad, Witherow, Chelsea, Patel, Prerana, Amoroso, Lucia, Schaer, Henry, Pittenger, Christopher, Kelmendi, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166878/
https://www.ncbi.nlm.nih.gov/pubmed/37181888
http://dx.doi.org/10.3389/fpsyt.2023.1178529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166878/
https://www.ncbi.nlm.nih.gov/pubmed/37181888
http://dx.doi.org/10.3389/fpsyt.2023.1178529

Ejemplares similares